2017
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma
Science Translational Medicine
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia
British Journal of Haematology
A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation
American Journal of Hematology
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
Oncotarget
IgM Myeloma: A Multicenter Retrospective Study of 134 Patients
American Journal of Hematology
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
Cell Reports
Proteomic characterization of human multiple myeloma bone marrow extracellular matrix
Leukemia
Prognostic role of circulating exosomal miRNAs in multiple myeloma
Blood
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma
American Journal of Hematology
Multiple Myeloma and the immune microenvironment
Current Cancer Drug Targets
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1
British Journal of Haematology
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
Annals of Oncology
Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance
Proceedings of the National Academy of Sciences (PNAS)
Established and Novel Prognostic Biomarkers in Multiple Myeloma
ASCO Educational Book
The LIN28B/let-7 axis a novel therapeutic pathways in Multiple Myeloma
History of Human Science (HHS)
Prospective, Multicenter Clinical Training of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia
Clinical Cancer Research
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma
Science Translational Medicine
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia
British Journal of Haematology
A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation
American Journal of Hematology
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
Oncotarget
IgM Myeloma: A Multicenter Retrospective Study of 134 Patients
American Journal of Hematology
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
Cell Reports
Proteomic characterization of human multiple myeloma bone marrow extracellular matrix
Leukemia
Prognostic role of circulating exosomal miRNAs in multiple myeloma
Blood
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma
American Journal of Hematology
Multiple Myeloma and the immune microenvironment
Current Cancer Drug Targets
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1
British Journal of Haematology
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
Annals of Oncology
Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance
Proceedings of the National Academy of Sciences (PNAS)
Established and Novel Prognostic Biomarkers in Multiple Myeloma
ASCO Educational Book
The LIN28B/let-7 axis a novel therapeutic pathways in Multiple Myeloma
History of Human Science (HHS)
Prospective, Multicenter Clinical Training of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia
Clinical Cancer Research